All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Daniel Pollyea | ASH 2018 | Venetoclax in combination with HMAs in patients with AML ineligible for intensive therapy
Bookmark this article
At the 2018 American Society of Hematology meeting, Daniel Pollyea from the University of Colorado School of Medicine, Denver, US, talks about data from an open-label, phase Ib, dose escalation and expansion trial, studying the safety and efficacy of venetoclax in combination with decitabine or azacitidine.
Venetoclax in combination with either azacitidine or decitabine led to high rates of rapid and deep responses that were durable in patients with acute myeloid leukemia (AML) ineligible for standard induction chemotherapy.
Venetoclax in combination with HMAs in patients with AML ineligible for intensive therapy
More about...
Your opinion matters
14 votes - 2 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox